• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

    9/4/24 8:00:00 AM ET
    $AVTX
    $DRRX
    $HALO
    $MESO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTX alert in real time by email

    KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives.

    "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next phase of growth," said Helena Chaye, Ph.D., CEO of KaliVir Immunotherapeutics. "Schond's appointment is a testament to our company's maturation and readiness to elevate our financial operations. His expertise will be crucial as we advance our mission to redefine cancer treatment with oncolytic virus therapy, execute our key objectives and maximize value for our stakeholders. This strategic addition to our leadership team underscores the remarkable progress we've made this year and positions us strongly for the exciting times ahead."

    Prior to joining KaliVir, Mr. Greenway served as CFO at MindMed (NASDAQ:MNMD), where he was responsible for all aspects of corporate finance, investor relations, public relations and information technology. He previously served as CFO at Avalo Therapeutics (NASDAQ:AVTX). Earlier in his career, he held executive leadership roles at Mesoblast Ltd (NASDAQ:MESO), Halozyme Therapeutics (NASDAQ:HALO), and DURECT Corporation (NASDAQ:DRRX). His investment banking career began at Morgan Stanley, and he later became Vice President, Healthcare Desk Analyst at Barclays Capital. Throughout his career, Mr. Greenway has played a pivotal role in advising and participating in transactions totaling more than $30 billion. He also played a critical role in securing more than $1.5 billion in growth equity, debt capital and R&D funding from biopharmaceutical companies during his leadership tenures at MindMed, Avalo Therapeutics, and other life sciences organizations.

    "Throughout my career, I have made it a priority to be a part of companies looking to advance new treatment paradigms that will make a difference in the lives of patients and I'm honored to play a role in KaliVir's journey to transform cancer care," said Schond Greenway, CFO of KaliVir Immunotherapeutics. "As the company's first CFO, I look forward to leveraging my experience in biotech finance to build a strong financial infrastructure that will support KaliVir's growth and innovation. I'm excited to join a team that's not only pushing the boundaries of science but also poised to create significant value for patients and shareholders alike."

    About KaliVir Immunotherapeutics, Inc.

    KaliVir Immunotherapeutics is a privately held biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. The company has developed a unique vaccinia virus-based platform, Vaccinia Enhanced Template (VET™) platform, that can generate potent novel oncolytic vaccinia viruses with modifications to maximize viral replication and enhance intravenous delivery and spread. The VET platform utilizes the large transgene capacity of the vaccinia virus to deliver therapeutics matched to tumor immunophenotypes to stimulate patients' immune systems and modify the tumor microenvironment. The company's lead clinical candidate VET3-TGI is now in Phase 1 development for the treatment of incurable, solid tumors. KaliVir's oncolytic virus candidates are designed to be safe, potent and systemically deliverable to treat cancer patients across multiple tumor types. KaliVir has announced collaborations with Roche and Astellas Pharma to design and generate novel oncolytic vaccinia viruses derived from the VET™ platform. In addition, Astellas entered into a world-wide exclusive license to develop and commercialize KaliVir's initial lead clinical candidate VET2-L2 oncolytic vaccinia virus. KaliVir is currently advancing multiple therapeutic candidates toward the clinic. For more information, please visit KaliVir.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240904799827/en/

    Get the next $AVTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTX
    $DRRX
    $HALO
    $MESO

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    Avalo Therapeutics Inc.
    $AVTX
    9/5/2025Buy
    TD Cowen
    Avalo Therapeutics Inc.
    $AVTX
    8/15/2025Overweight
    Cantor Fitzgerald
    Halozyme Therapeutics Inc.
    $HALO
    8/6/2025$75.00Equal-Weight → Overweight
    Morgan Stanley
    Mind Medicine (MindMed) Inc.
    $MNMD
    8/4/2025$25.00Outperform
    Oppenheimer
    Mesoblast Limited
    $MESO
    7/18/2025Buy → Hold
    Jefferies
    Halozyme Therapeutics Inc.
    $HALO
    7/10/2025$55.00Neutral
    Goldman
    Avalo Therapeutics Inc.
    $AVTX
    6/2/2025$15.00Buy
    H.C. Wainwright
    More analyst ratings

    $AVTX
    $DRRX
    $HALO
    $MESO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Asen R Scott bought $11,357 worth of shares (5,917 units at $1.92), increasing direct ownership by 0.22% to 2,672,529 units (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    8/26/25 3:41:18 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Asen R Scott bought $386,666 worth of shares (204,220 units at $1.89), increasing direct ownership by 5% to 2,666,612 units (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    8/22/25 6:10:18 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gryska David W bought $17,925 worth of shares (2,500 units at $7.17), increasing direct ownership by 14% to 19,851 units (SEC Form 4)

    4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

    12/5/24 4:30:05 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $AVTX
    $DRRX
    $HALO
    $MESO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Sullivan Mark sold $110,186 worth of shares (11,278 units at $9.77), decreasing direct ownership by 4% to 293,852 units (SEC Form 4)

    4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

    9/26/25 5:35:36 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Barrow Robert sold $252,037 worth of shares (25,797 units at $9.77), decreasing direct ownership by 3% to 804,268 units (SEC Form 4)

    4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

    9/26/25 5:35:13 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Medical Officer Karlin Daniel sold $75,268 worth of shares (7,704 units at $9.77), decreasing direct ownership by 2% to 430,625 units (SEC Form 4)

    4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

    9/26/25 5:34:29 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $AVTX
    $DRRX
    $HALO
    $MESO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

    Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation Two of Elektrofi's partners projected to begin Hypercon™ formulated product clinical development by year end 2026, or earlier Halozyme to host conference call and webcast today at 5:30am PT/ 8:30am ET SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it has entered into a definitive agreement to acquire Elektrofi, Inc. ("Elektrofi"), a biopharm

    10/1/25 7:00:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

    WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. "We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year," said Dr. Garry Nei

    10/1/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

    NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products are manufactured from U.S. donors in the U.S. and designated as U.S. origin products not subject to tariffs on imported branded or patented pharmaceutical products. Ryoncil® (remestemcel-L) is the only allogeneic mesenchymal stromal cell therapy approved by U.S. Food and Drug Administration (FDA) for any indication. As documented in the Company's Biologic License Application (BLA), Ryoncil® is designated a ‘U.S. Country of Origin' product in line with U.S. FDA and Customs

    9/26/25 1:49:36 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVTX
    $DRRX
    $HALO
    $MESO
    SEC Filings

    View All

    Halozyme Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

    10/1/25 7:06:21 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Avalo Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

    10/1/25 7:01:23 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Mesoblast Limited

    6-K - MESOBLAST LTD (0001345099) (Filer)

    9/29/25 7:22:09 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVTX
    $DRRX
    $HALO
    $MESO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for POSIMIR

    Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form

    2/2/21 7:24:30 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $DRRX
    $HALO
    $MESO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright reiterated coverage on Avalo Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $25.00 from $15.00 previously

    9/17/25 11:38:46 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Avalo Therapeutics

    TD Cowen initiated coverage of Avalo Therapeutics with a rating of Buy

    9/5/25 7:58:24 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Avalo Therapeutics

    Cantor Fitzgerald initiated coverage of Avalo Therapeutics with a rating of Overweight

    8/15/25 8:18:27 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $DRRX
    $HALO
    $MESO
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

    WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. "We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year," said Dr. Garry Nei

    10/1/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

    WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit. "Kevin joins Avalo at an exciting time, as we continue to advance AVTX-009 through the Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with topline data expected mid next year," said

    9/22/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

    WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. "We are pleased to welcome Dr. Jain to Avalo's Board of Directors," said Michael Heffernan, Chairman of the Board. "Rita's extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biopharma companies will be invaluable as we continue to advance AVTX-009, a high affinity anti-IL-1β monoclonal antibody in a Phase 2 trial for hidradenitis suppurativa (HS) and take a thought

    6/18/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    $DRRX
    $HALO
    $MESO
    Financials

    Live finance-specific insights

    View All

    Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

    Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation Two of Elektrofi's partners projected to begin Hypercon™ formulated product clinical development by year end 2026, or earlier Halozyme to host conference call and webcast today at 5:30am PT/ 8:30am ET SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it has entered into a definitive agreement to acquire Elektrofi, Inc. ("Elektrofi"), a biopharm

    10/1/25 7:00:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

    Total Revenue Increased 41% YOY to $326 million and Royalty Revenue Increased 65% YOY to $206 million Net Income Increased 77% YOY to $165 million; Adjusted EBITDA Increased 65% YOY to $226 million; GAAP Diluted EPS Increased 85% YOY to $1.33; Non-GAAP Diluted EPS Increased 69% YOY to $1.541 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,275 - $1,355 million, Representing YOY Growth of 26% - 33%, Adjusted EBITDA to $865 - $915 million, Representing YOY Growth of 37% - 45% and Non-GAAP Diluted EPS to $6.00 - $6.40, Representing YOY Growth of 42% - 51%1 Announcing Third $250 million Share Repurchase Tranche Under $750 million Authorized Plan  SAN DIEGO, Aug. 5, 2025 /PRNewswir

    8/5/25 4:01:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MindMed Reports Q2 2025 Financial Results and Business Updates

    --Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)-- --Data from the Phase 3 Voyage trial in GAD anticipated in 1H 2026 and data from the Phase 3 Panorama trial in GAD and Phase 3 Emerge trial in MDD anticipated in 2H 2026-- --Strengthened leadership team with appointment of Brandi L. Roberts as Chief Financial Officer-- --Conference call scheduled today at 4:30 p.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders,

    7/31/25 4:01:00 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $AVTX
    $DRRX
    $HALO
    $MESO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by DURECT Corporation

    SC 13G/A - DURECT CORP (0001082038) (Subject)

    11/19/24 5:10:25 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care